Participated · Series C · Jul 2021

Element Biosciences develops platforms that generate genetic, molecular and cellular data by reading the genetic code of organisms including humans, plants, animals and microbes. The company positions its technology to support precision medicine, disease research, agriculture and forensics by enabling genomic and multiomic insights. Led by CEO Molly He, Element has been building a commercial ecosystem of genomic and multiomic solutions. The company said it will use proceeds from the Series E to accelerate commercialization, expand globally, and advance its product roadmap across research, translational science and diagnostic applications. Financially, Element announced this Series E after raising $277M in a Series D in July 2024 and secured $175M from Samsung Electronics in the current round with additional undisclosed investors. No revenue or user metrics were disclosed in the article.

Participated · Series A · Sep 2015

Tunitas Therapeutics is a San Francisco, CA-based biopharmaceutical company focused on novel targeted protein therapeutics for allergy sufferers. The company is led by Nolan Sigal, M.D., Ph.D., President and Chief Executive Officer. Its lead candidate is a fusion protein called epsi-gam. Tunitas intends to use recent financing to advance epsi-gam through initial Phase 1 clinical trials and to initiate Phase 2a studies. The company plans to develop epsi-gam as a potential treatment for patients with moderate to severe asthma and for patients with severe, potentially life-threatening food allergies. Tunitas closed a $10M Series A venture financing to support these development milestones.